295 related articles for article (PubMed ID: 26586345)
1. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
Li Z; Jiang K; Zhu X; Lin G; Song F; Zhao Y; Piao Y; Liu J; Cheng W; Bi X; Gong P; Song Z; Meng S
Cancer Lett; 2016 Jan; 370(2):332-44. PubMed ID: 26586345
[TBL] [Abstract][Full Text] [Related]
2. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
3. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
4. Development of encorafenib for BRAF-mutated advanced melanoma.
Koelblinger P; Thuerigen O; Dummer R
Curr Opin Oncol; 2018 Mar; 30(2):125-133. PubMed ID: 29356698
[TBL] [Abstract][Full Text] [Related]
5. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
6. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
7. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
Xie X; Koh JY; Price S; White E; Mehnert JM
Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
[TBL] [Abstract][Full Text] [Related]
8. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
9. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
10. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
Jang GH; Lee M
Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
12. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
Yang H; Higgins B; Kolinsky K; Packman K; Go Z; Iyer R; Kolis S; Zhao S; Lee R; Grippo JF; Schostack K; Simcox ME; Heimbrook D; Bollag G; Su F
Cancer Res; 2010 Jul; 70(13):5518-27. PubMed ID: 20551065
[TBL] [Abstract][Full Text] [Related]
13. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
14. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C
J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597
[TBL] [Abstract][Full Text] [Related]
15. Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells.
Yu XJ; Han QB; Wen ZS; Ma L; Gao J; Zhou GB
Cancer Lett; 2012 Sep; 322(2):185-94. PubMed ID: 22410463
[TBL] [Abstract][Full Text] [Related]
16. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
[TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib induces senescence features in melanoma cells.
Haferkamp S; Borst A; Adam C; Becker TM; Motschenbacher S; Windhövel S; Hufnagel AL; Houben R; Meierjohann S
J Invest Dermatol; 2013 Jun; 133(6):1601-9. PubMed ID: 23321925
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]